Key result
Reverse ramp testing improves assessment of myocardial recovery to guide LVAD weaning.
Why the study?
Assessment of true left ventricular ejection fraction during LVAD support is challenging, complicating identification of patients with myocardial recovery and optimal device explantation criteria.
Answers are grounded in this paper and cite their sources.
May aid weaning decisions via unmasked LVAD recovery assessment; leaves open prospective validation of explant success.
Mechanical unloading with left ventricular assist device (LVAD) support can lead to clinically meaningful reversal of stress-related compensatory mechanisms. However, true assessment of left ventricular ejection fraction (LVEF) is not possible, whereas the left ventricle is unloaded by LVAD therapy making identification of patients with myocardial recovery even more challenging. We introduce our new protocol, the "reverse ramp test" for HeartWare HVAD, HeartMate II, and HeartMate 3. The reverse ramp is transthoracic echo (TTE) and right heart catheterization (RHC)-based protocol with LVAD turn down steps to minimal support allowing for a more accurate assessment of myocardial function.
No takes yet. Share an insight, caveat, or question.
Holzhauser et al. (2019) conducted a review in Heart failure with left ventricular assist device (LVAD) support. Reverse ramp test protocol was evaluated. The reverse ramp test, a protocol utilizing echocardiography and right heart catheterization with LVAD turn-down steps, facilitates more accurate assessment of myocardial recovery for device weaning.
Synapse has enriched 10 related papers. Consider them for comparative context: